Ralevski 2007.

Trial name or title	Topiramate for treatment of patients with borderline personality disorder and alcohol dependence
Methods	Randomised placebo‐controlled double‐blind trial
Participants	30 participants Inclusion criteria: 21 to 60 years old; both genders; diagnosis of alcohol dependence; diagnosis of borderline personality disorder Exclusion criteria: serious or unstable medical condition; opiate dependence; major Axis I disorder; taking mood stabilisers and antipsychotic medications; liver functional test abnormalities that do not exceed three times normal values
Interventions	(1) Topiramate plus SSRI; (2) placebo plus SSRI Drug dose: topiramate 250 mg/d Duration: eight weeks. Country of origin: USA
Outcomes	Primary outcomes: drinking; craving; aggression Secondary outcomes: affect; adverse effects
Starting date	March 2007
Contact information	Elizabeth Ralevski, PhD, +120 393 25711, ext 4282, elizabeth.ralevski@yale.edu, Yale University, VA Connecticut Healthcare System, West Haven, Connecticut, United States 06516
Notes